Mirum Pharmaceuticals, Inc. Depreciation Expense on Reclassified Assets
Mirum Pharmaceuticals, Inc. (MIRM) reported Depreciation Expense on Reclassified Assets of $300.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DepreciationExpenseOnReclassifiedAssets · last filed 2026-02-25
- Mirum Pharmaceuticals, Inc. depreciation expense on reclassified assets for fiscal 2025 was $300.00K, a 40.00% decline from fiscal 2024.
- Mirum Pharmaceuticals, Inc. depreciation expense on reclassified assets for fiscal 2024 was $500.00K, a 66.67% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. depreciation expense on reclassified assets for fiscal 2023 was $300.00K, a 0.00% change from fiscal 2022.
- Mirum Pharmaceuticals, Inc. depreciation expense on reclassified assets for fiscal 2022 was $300.00K, a 0.00% change from fiscal 2021.
| Period end | Depreciation Expense on Reclassified Assets 12 month |
|---|---|
| 2025-12-31 | $300.00K 10-K · filed 2026-02-25 |
| 2024-12-31 | $500.00K 10-K · filed 2026-02-25 |
| 2023-12-31 | $300.00K 10-K · filed 2026-02-25 |
| 2022-12-31 | $300.00K 10-K · filed 2025-02-26 |
| 2021-12-31 | $300.00K 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |